Comparative Pharmacology
Head-to-head clinical analysis: INDIUM IN 111 OXYQUINOLINE versus IODOTOPE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDIUM IN 111 OXYQUINOLINE versus IODOTOPE.
INDIUM IN 111 OXYQUINOLINE vs IODOTOPE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indium In 111 oxyquinoline is a radiolabeled compound that chelates indium-111 with oxyquinoline. The lipophilic complex penetrates cell membranes and binds to intracellular components, primarily in leukocytes (neutrophils). After intravenous injection, the radiolabeled cells accumulate at sites of inflammation or infection, allowing gamma camera imaging to detect focal areas of abnormal leukocyte localization.
Iodine-131 is taken up by the thyroid gland and emits beta particles and gamma rays, causing destruction of thyroid tissue via radiation-induced cell death.
1-2 mCi (37-74 MBq) labeled autologous leukocytes, administered intravenously over 1-2 minutes.
For thyroid ablation: 3.7-5.55 MBq (100-150 μCi) orally as a single dose. For hyperthyroidism: 185-555 MBq (5-15 mCi) orally as a single dose.
None Documented
None Documented
Terminal elimination half-life is approximately 4-6 hours for the free indium ion, but biological half-life for labeled cells can be 1-2 days depending on cell type.
Terminal half-life is approximately 120-140 days for total body iodine, but the effective half-life for therapeutic use is 8-13 days due to biological turnover in the thyroid. For diagnostic use, effective half-life is 1-2 days.
Renal excretion approximately 70-80% within 24 hours; fecal excretion less than 5%.
Primarily renal: >90% excreted in urine as iodide. Fecal excretion is negligible (<2%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical